Current advances in Hodgkin's lymphoma

Chronic Diseases and Translational Medicine - Tập 5 - Trang 15-24 - 2019
Joseph Vadakara1, Benjamin Andrick1
1Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822, USA

Tóm tắt

AbstractHodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.

Tài liệu tham khảo

10.1002/hon.723 10.1177/095952873201700106 10.1093/annonc/13.S1.79 10.1016/j.ijrobp.2013.05.005 10.1001/jama.1946.02870380008004 Carbone P.P., 1968, Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids, Cancer Res, 28, 811 10.7326/0003-4819-73-6-881 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7 10.1056/NEJMoa022473 10.1056/NEJMoa1100340 10.1200/JCO.2015.64.5648 10.1182/blood.V128.22.1183.1183 10.1007/s12185-016-2080-5 Skoetz N., 2017, Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma, Cochrane Database Syst Rev, 5, CD007941 10.1200/JCO.1995.13.5.1080 10.1200/JCO.2012.43.4803 10.1182/blood-2017-10-811224 10.1007/s40265-017-0705-5 10.1200/JCO.2017.76.0793 10.1056/NEJMoa1510093 10.1016/S0140-6736(17)32134-7 10.1056/NEJMoa1408648 10.1056/NEJMoa1708984 10.1182/blood-2016-03-703470 10.1182/blood.V130.Suppl_1.734.734 10.1016/S1470-2045(17)30696-4 10.1016/S0140-6736(11)61940-5 10.1002/hon.2437_69 10.1200/jco.2015.33.15_suppl.8505 10.1002/hon.2437_68 10.1182/blood-2015-06-644336 10.1182/blood-2017-06-787200 10.1200/JCO.2011.38.0410 10.1182/blood-2016-02-699850 10.1016/S0140-6736(15)60165-9 10.1016/j.bbmt.2015.11.315 10.1182/blood.V130.Suppl_1.738.738 10.1182/blood-2017-11-815183 10.1182/blood.V128.22.4146.4146 10.1182/blood.V128.22.1109.1109 10.1182/blood.V128.22.1834.1834 10.1200/JCO.2016.72.1316 10.1200/JCO.2018.36.15_suppl.7537 Ansell S.M., 2017, A phase 1 study investigating the combination of AFM13 and the monoclonal anti‐PD‐1 antibody pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study, Blood, 13, 1522 10.1200/JCO.2018.36.15_suppl.7536 10.1186/s13045-015-0188-3 10.1182/blood-2014-12-614636 10.1002/path.1725 10.1186/s40164-018-0103-z 10.1182/blood-2010-05-282780 10.1182/blood.V128.22.1820.1820 10.3324/haematol.2017.180554 10.1056/NEJMc1505857 10.1182/blood-2013-06-507947 10.1186/1756-8722-2-36 10.1182/blood-2011-07-362475 10.1200/JCO.2013.51.5304 10.1172/JCI94306 10.1158/1078-0432.CCR-16-1365
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 5

15-24

Thông tin tác giả